Details of the Drug

General Information of Drug (ID: DMDUVCZ)

Drug Name

IPH-2101

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Phase 2	[1]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MHC class I NK cell receptor 2DL1 (CD158A)	TT4UXPE	KI2L1_HUMAN	Modulator	[2]
MHC class I NK cell receptor 2DL2 (CD158b1)	TTU0P73	KI2L2_HUMAN	Modulator	[2]
MHC class I NK cell receptor 2DL3 (CD158b2)	TTEX3SI	KI2L3_HUMAN	Modulator	[2]
MHC class I NK cell receptor 2DS1 (CD158h)	TTVWAGF	KI2S1_HUMAN	Modulator	[2]
MHC class I NK cell receptor 2DS2 (CD158j)	TTV3CFI	KI2S2_HUMAN	Modulator	[2]

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

02 Neoplasm

Disease Class

ICD-11: 2C82 Prostate cancer

The Studied Tissue

Bone marrow

The Studied Disease

Multiple myeloma [ICD-11:2C82]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
MHC class I NK cell receptor 2DL2 (CD158b1)	DTT	KIR2DL2	1.69E-05	-0.93	-3.58
MHC class I NK cell receptor 2DL3 (CD158b2)	DTT	KIR2DL3	5.34E-04	-0.32	-2.19
MHC class I NK cell receptor 2DL1 (CD158A)	DTT	KIR2DL1	2.29E-06	-0.43	-4.42

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01222286) Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma. U.S. National Institutes of Health.
2	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.